5th RNA Editing Summit

Kongressthemen
Welcome to the 5th RNA Editing Summit
Pioneering RNA Editing Drugs Towards Clinical Realities
Despite remarkable advancements, such as Wave Life Sciences pioneering the first clinical candidate and significant investments like Ascidian Therapeutics securing $40 million for their RNA editing pipeline, challenges persist in optimizing delivery and ensuring treatment longevity for new RNA editing therapies.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2221213-3?pid=4832

Speakers: Andrew Fraley, Chief Technology Officer, Entrepreneur In Residence, Judo Bio, Atlas Venture, C. Anthony Altar, President and Chief Operating Officer, Splice Therapeutics, and more

https://go.evvnt.com/2221213-2?pid=4832

Frau Isabella Hunter